Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications hifmech study group plasma fibrinogen concentration predicts risk myocardial infarction
… among patients with end-stage renal disease to inform study design decisions Layton JB , McGrath LJ, Sahrmann JM, … patterns of healthcare utilization, aspects of the study design such as the length of the lookback period or the … these observed patterns. For example, in the comparative study based on this work, we extended the pre-vaccination …
… effect of your medicine in any particular controlled group. However, some patients in your study will benefit more or less than the average. Who are … for market segmentation - Provide evidence for possible risk-sharing plans for reimbursement Regulatory Approval - …
… patient committee participants on the FDA-sponsored study to adapt an in-clinic outcome assessment tool for ALS …
… HCPs towards hepatitis A and B vaccination of adults at risk. Shamarina D, Sluga-O'Callaghan M, Dave V, Davenport E, …
… 21st British Thoracic Oncology Group Annual Conference Share on: Wednesday, April 26 - … NSCLC: UK subgroup analysis of a global real-world study. Escriu C, Rathinam S, Kahangire DA, Nagar SP, Davis …
… Publication Management and Medical Writing Publications are critical for the dissemination of your … and internal milestones is an integral part of the publications process. We develop a customized timeline for … following best practices. Our publication managers submit publications to journals across the spectrum of scientific …
… and administer the survey: We recruit subjects for each study that are representative of the target patient … data and provide reports and manuscripts : We provide study reports, manuscripts for peer-reviewed journals , and …
… results (e.g., scientific conferences, peer-reviewed publications ) …
… of different techniques may be required within a single study. We are able to fit MTCs to wide variety of different …
IPECAD Cross Comparison Challenge on Cost-Effectiveness Models in Alz Disease and Related Dementias William L Herring, PhD Executive Director, Health Economics Transcript As disease-modifying therapies for Alzheimer’s disease, or AD, enter the market, …